Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung Cancer

National Institute of Cancerología200 enrolled

Overview

The purpose of the study is to evaluate the association between the number of circulating tumor cells and response to treatment in non small-cell lung cancer patients

In spite of technological advantages in diagnosis and treatment, lung cancer remains one of the most deadly malignant neoplasias. Moreover, there are no markers for monitoring response to treatment. The objective of the study is to associate the number of circulating tumor cells (CTC) before and after treatment and correlate it with tumor response rate, progression-free survival and overall survival.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Circulating Tumor Cells

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histopathologic diagnosis of non small-cell lung cancer * Clinical stage IV * ECOG functional status 0 or 1 * No renal function alteration (GFR \>50%) * No hepatic function alteration (ALT and AST less than 2 times its normal value) * Leucocytes more than 2,000/mcl * Hemoglobin more than 10mg/dL * Platelets more than 100,000/mcl Exclusion Criteria: Non-advanced disease

Locations (1)

National Institute of Cancerologia

Mexico City, Mexico City, Mexico

RECRUITING

Outcomes

Primary Outcomes

Response rate, progression-free survival and over-all survival

Time frame: 4 years

Secondary Outcomes

Quantification of CTCs

Time frame: 4 years

Central Contacts

Oscar Arrieta, MD

CONTACT

(0155)56280400 ogar@servidor.unam.mx

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.